Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Effect of alfacalcidol on bone mineral density and bone turnover markers in postmenopausal women

XIA Chun-xiao,CAI Xi,CHEN Qi-yu,MA Xiang-ai Department of Obstetrics and Gynecology,Second Affiliated Hospital,Wenzhou medical College,Wenzhou,Zhejiang 325027,China  
Objective To evaluate the effect of alfacalcidol on bone mineral density(BMD) and bone turnover markers in postmenopausal women.Methods A total of 67 postmenopausal women aged from 55-75 years with low BMD or osteoporosis from Sep.2009 to Dec.2011were enrolled into the study.They were randomly divided into 2 groups.Subjects in experimental group were taking Osteoform 1000 mg/d and alfacalcidol 0.25 μg/bid orally,while those in control group were only taking osteoform 1000mg/d.After 48 weeks of medication,BMD of femoral neck,the greater trochanter,Ward′s triangle area and lumbar1-4 were measured by X-ray.Meanwhile,some biochemical markers of bone turnover such as bone alkaline phosphatase(BALP),Tartrate-resistant acid phosphatase(TRACP)and 25-hydroxychole calciferol[25(OH)D3]were also measured by enzyme linked immunosorbent assay(ELISA).Results There was no significant difference of BMD between two groups(P0.05) prior to treatment.The BMD of every bone measured increased significantly in experimental group after treatment(P0.05),while only BMD of lumbar 2-4 showed improvement after treatment in control group.There was a statistically difference for BMD of every measured bone between two groups after treatment(P0.05).We also found that before treatment there were no differences in terms of the serum levels of BALP,TRACP and 25(OH)D3 between two groups(P0.05).But the differences were significant after treatment(P0.05).In experimental group,the serum level of BALP,TRACP and 25(OH)D3 changed from 26.52±6.07 μg/L,2.84±0.97 U/L and 53.91±19.04 nmol/L before treatment to 21.85±5.96 μg/L,2.37±0.88 U/L and 57.87±19.24 nmol/L after treatment,while they did not change a lot in control group before and after the treatment(P0.05).Conclusions Alfacalcidol could be used for the treatment of postmenopausal osteoporosis by increasing bone mineral density and reducing bone turnover markers.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved